Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

John P. Manis, M.D.

Co-Author

This page shows the publications co-authored by John Manis and Frederick Alt.
Connection Strength

3.755
  1. Novel antibody switching defects in human patients. J Clin Invest. 2003 Jul; 112(1):19-22.
    View in: PubMed
    Score: 0.279
  2. Elucidation of a downstream boundary of the 3' IgH regulatory region. Mol Immunol. 2003 Jan; 39(12):753-60.
    View in: PubMed
    Score: 0.269
  3. IgH class switch recombination to IgG1 in DNA-PKcs-deficient B cells. Immunity. 2002 Apr; 16(4):607-17.
    View in: PubMed
    Score: 0.256
  4. Mechanism and control of class-switch recombination. Trends Immunol. 2002 Jan; 23(1):31-9.
    View in: PubMed
    Score: 0.251
  5. Class switching in B cells lacking 3' immunoglobulin heavy chain enhancers. J Exp Med. 1998 Oct 19; 188(8):1421-31.
    View in: PubMed
    Score: 0.201
  6. Ku70 is required for late B cell development and immunoglobulin heavy chain class switching. J Exp Med. 1998 Jun 15; 187(12):2081-9.
    View in: PubMed
    Score: 0.196
  7. Orientation-specific joining of AID-initiated DNA breaks promotes antibody class switching. Nature. 2015 Sep 03; 525(7567):134-139.
    View in: PubMed
    Score: 0.162
  8. Immature B cells preferentially switch to IgE with increased direct Sµ to Se recombination. J Exp Med. 2011 Dec 19; 208(13):2733-46.
    View in: PubMed
    Score: 0.125
  9. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. Proc Natl Acad Sci U S A. 2011 Feb 15; 108(7):2873-8.
    View in: PubMed
    Score: 0.118
  10. Analysis of mice lacking DNaseI hypersensitive sites at the 5' end of the IgH locus. PLoS One. 2010 Nov 15; 5(11):e13992.
    View in: PubMed
    Score: 0.116
  11. Alternative end-joining catalyzes class switch recombination in the absence of both Ku70 and DNA ligase 4. J Exp Med. 2010 Feb 15; 207(2):417-27.
    View in: PubMed
    Score: 0.110
  12. Downstream class switching leads to IgE antibody production by B lymphocytes lacking IgM switch regions. Proc Natl Acad Sci U S A. 2010 Feb 16; 107(7):3040-5.
    View in: PubMed
    Score: 0.110
  13. IgH class switching and translocations use a robust non-classical end-joining pathway. Nature. 2007 Sep 27; 449(7161):478-82.
    View in: PubMed
    Score: 0.093
  14. Evolution of the immunoglobulin heavy chain class switch recombination mechanism. Adv Immunol. 2007; 94:157-214.
    View in: PubMed
    Score: 0.089
  15. Pathways that suppress programmed DNA breaks from progressing to chromosomal breaks and translocations. DNA Repair (Amst). 2006 Sep 08; 5(9-10):1030-41.
    View in: PubMed
    Score: 0.087
  16. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell. 2006 Jan 20; 21(2):201-14.
    View in: PubMed
    Score: 0.083
  17. The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. Nature. 2005 Nov 24; 438(7067):508-11.
    View in: PubMed
    Score: 0.082
  18. Artemis-independent functions of DNA-dependent protein kinase in Ig heavy chain class switch recombination and development. Proc Natl Acad Sci U S A. 2005 Feb 15; 102(7):2471-5.
    View in: PubMed
    Score: 0.078
  19. 53BP1 links DNA damage-response pathways to immunoglobulin heavy chain class-switch recombination. Nat Immunol. 2004 May; 5(5):481-7.
    View in: PubMed
    Score: 0.074
  20. Artemis and p53 cooperate to suppress oncogenic N-myc amplification in progenitor B cells. Proc Natl Acad Sci U S A. 2004 Feb 24; 101(8):2410-5.
    View in: PubMed
    Score: 0.073
  21. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell. 2003 Aug 08; 114(3):359-70.
    View in: PubMed
    Score: 0.070
  22. Leaky Scid phenotype associated with defective V(D)J coding end processing in Artemis-deficient mice. Mol Cell. 2002 Dec; 10(6):1379-90.
    View in: PubMed
    Score: 0.067
  23. Internal IgH class switch region deletions are position-independent and enhanced by AID expression. Proc Natl Acad Sci U S A. 2002 Jul 23; 99(15):9984-9.
    View in: PubMed
    Score: 0.065
  24. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell. 2002 Jun 28; 109(7):811-21.
    View in: PubMed
    Score: 0.065
  25. The function of AID in somatic mutation and class switch recombination: upstream or downstream of DNA breaks. J Exp Med. 2002 May 06; 195(9):F37-41.
    View in: PubMed
    Score: 0.064
  26. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol Cell. 2000 Jun; 5(6):993-1002.
    View in: PubMed
    Score: 0.056
  27. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature. 2000 Apr 20; 404(6780):897-900.
    View in: PubMed
    Score: 0.056
  28. The interplay between nonhomologous end-joining and cell cycle checkpoint factors in development, genomic stability, and tumorigenesis. Cold Spring Harb Symp Quant Biol. 2000; 65:395-403.
    View in: PubMed
    Score: 0.055
  29. Position-dependent inhibition of class-switch recombination by PGK-neor cassettes inserted into the immunoglobulin heavy chain constant region locus. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):3000-5.
    View in: PubMed
    Score: 0.052
  30. Nonhomologous end-joining proteins are required for V(D)J recombination, normal growth, and neurogenesis. Cold Spring Harb Symp Quant Biol. 1999; 64:169-81.
    View in: PubMed
    Score: 0.051
  31. Ig heavy chain class switching in Rag-deficient mice. Int Immunol. 1998 Mar; 10(3):325-32.
    View in: PubMed
    Score: 0.048
  32. Growth retardation and leaky SCID phenotype of Ku70-deficient mice. Immunity. 1997 Nov; 7(5):653-65.
    View in: PubMed
    Score: 0.047
  33. Integrity of the AID serine-38 phosphorylation site is critical for class switch recombination and somatic hypermutation in mice. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2717-22.
    View in: PubMed
    Score: 0.026
  34. Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching. J Exp Med. 2008 Dec 22; 205(13):3079-90.
    View in: PubMed
    Score: 0.025
  35. S-S synapsis during class switch recombination is promoted by distantly located transcriptional elements and activation-induced deaminase. Immunity. 2007 Nov; 27(5):711-22.
    View in: PubMed
    Score: 0.024
  36. Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas. Oncogene. 2008 Jan 10; 27(3):318-22.
    View in: PubMed
    Score: 0.023
  37. 53BP1 and p53 synergize to suppress genomic instability and lymphomagenesis. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3310-5.
    View in: PubMed
    Score: 0.021
  38. MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell. 2006 Jan 20; 21(2):187-200.
    View in: PubMed
    Score: 0.021
  39. p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell. 2004 Jul; 6(1):85-9.
    View in: PubMed
    Score: 0.019
  40. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10794-9.
    View in: PubMed
    Score: 0.018
  41. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med. 2003 May 05; 197(9):1213-9.
    View in: PubMed
    Score: 0.017
  42. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001 Jul 19; 412(6844):300-7.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.